Meeting
2015 ASCO Annual Meeting
A phase I study of temsirolimus plus erlotinib in patients with refractory solid tumors.
Authors
Andrea Wang-Gillam
Division of Oncology, Washington University in St. Louis, St. Louis, MO
Andrea Wang-Gillam , Benjamin R. Tan Jr., Saiama Naheed Waqar , Rama Suresh , Daniel Morgensztern , Brian Andrew Van Tine , Rebecca Nieman , Ramaswamy Govindan , Albert C. Lockhart
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Signal Transduction
Clinical Trial Registration Number
NCT00770263
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2600)
DOI
10.1200/jco.2015.33.15_suppl.2600
Abstract #
2600
Poster Bd #
316
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Phase I/IB multicenter study of afatinib in combination with capecitabine in patients (pts) with refractory solid tumors and pancreatico-biliary cancers.
First Author: Amy E. Chang
Poster
2016 ASCO Annual Meeting
Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib.
First Author: Zev A. Wainberg
Poster
2015 ASCO Annual Meeting
Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumors.
First Author: Antoine Hollebecque
Poster
2012 ASCO Annual Meeting
Phase I trial of temsirolimus (TEM), irinotecan (IRN), and temozolomide (TMZ) in children with refractory solid tumors: A Children's Oncology Group study.
First Author: Rochelle Bagatell